GENFIT (GNFT.PA) Stock Price & Overview
EPA:GNFT • FR0004163111
The current stock price of GNFT.PA is 8.52 EUR. Today GNFT.PA is down by -2.57%. In the past month the price increased by 39.79%. In the past year, price increased by 147.32%.
GNFT.PA Key Statistics
- Market Cap
- 426.025M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.70
- Dividend Yield
- N/A
GNFT.PA Stock Performance
GNFT.PA Stock Chart
GNFT.PA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to GNFT.PA. When comparing the yearly performance of all stocks, GNFT.PA is one of the better performing stocks in the market, outperforming 98.93% of all stocks.
GNFT.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GNFT.PA. GNFT.PA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
GNFT.PA Earnings
On February 26, 2026 GNFT.PA reported an EPS of -0.2 and a revenue of 33.49M. The company missed EPS expectations (-119.13% surprise) and missed revenue expectations (-66.69% surprise).
GNFT.PA Forecast & Estimates
12 analysts have analysed GNFT.PA and the average price target is 11.18 EUR. This implies a price increase of 31.21% is expected in the next year compared to the current price of 8.52.
For the next year, analysts expect an EPS growth of -229.07% and a revenue growth -34.41% for GNFT.PA
GNFT.PA Groups
Sector & Classification
GNFT.PA Financial Highlights
Over the last trailing twelve months GNFT.PA reported a non-GAAP Earnings per Share(EPS) of -0.7. The EPS decreased by -289.19% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -17.98% | ||
| ROE | -74.24% | ||
| Debt/Equity | 0.1 |
GNFT.PA Ownership
GNFT.PA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 24.06 | 38.751B | ||
| ARGX | ARGENX SE | 24.11 | 38.739B | ||
| 22UA | BIONTECH SE-ADR | N/A | 20.871B | ||
| ABVX | ABIVAX SA | N/A | 7.836B | ||
| 2X1 | ABIVAX SA | N/A | 7.812B | ||
| GXE | GALAPAGOS NV | N/A | 1.904B | ||
| GLPG | GALAPAGOS NV | N/A | 1.899B | ||
| NANO | NANOBIOTIX | N/A | 1.396B | ||
| 6IV | INVENTIVA SA | N/A | 1.174B | ||
| IVA | INVENTIVA SA | N/A | 1.096B | ||
| PHIL | PHILOGEN SPA | 17.21 | 614.04M | ||
| AYJ | VALNEVA SE | N/A | 417.758M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About GNFT.PA
Company Profile
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company is headquartered in Loos, Hauts-De-France and currently employs 188 full-time employees. The company went IPO on 2006-12-19. The firm provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The firm leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.
Company Info
GENFIT
Parc Eurasante 885 avenue Eugene Avinee
LOOS HAUTS-DE-FRANCE FR
Employees: 169
Phone: 33320164000
GENFIT / GNFT.PA FAQ
What does GNFT do?
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company is headquartered in Loos, Hauts-De-France and currently employs 188 full-time employees. The company went IPO on 2006-12-19. The firm provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The firm leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.
What is the current price of GNFT stock?
The current stock price of GNFT.PA is 8.52 EUR. The price decreased by -2.57% in the last trading session.
What is the dividend status of GENFIT?
GNFT.PA does not pay a dividend.
What is the ChartMill rating of GENFIT stock?
GNFT.PA has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting GNFT stock to perform?
12 analysts have analysed GNFT.PA and the average price target is 11.18 EUR. This implies a price increase of 31.21% is expected in the next year compared to the current price of 8.52.
Would investing in GENFIT be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on GNFT.PA.